Kintara Therapeutics is developing innovative cancer therapies for rare, unmet medical needs
- Kintara Therapeutics says VAL-083 treatment arm in the Phase 2/3 clinical trial for glioblastoma multiforme now activated in 26 US sites
- Kintara Therapeutics enrolls patients at 26 sites within around 7 months
Quick facts: Kintara Therapeutics
Price: 1.32 USD
Market Cap: $43.06 m
About the company
Located in San Diego, California, Kintara is dedicated to the development of novel cancer therapies for patients with unmet medical needs. Kintara is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for cutaneous metastatic breast cancer (CMBC).
Kintara's REM-001 is a proprietary, late-stage photodynamic therapy platform that holds promise as a localized cutaneous, or visceral, tumor treatment as well as in other potential indications. REM-001 therapy, has been previously studied in four Phase 2/3 clinical trials in patients with CMBC, who had previously received chemotherapy and/or failed radiation therapy. With clinical efficacy to date of 80% complete responses of CMBC evaluable lesions, and with an existing robust safety database of approximately 1,100 patients across multiple indications, Kintara is advancing the REM-001 CMBC program to late-stage pivotal testing.
How it is doing
Kintara Therapeutics (NASDAQ:KTRA) Inc has announced that the VAL-083 treatment arm in the Global Coalition for Adaptive Research (GCAR) registrational Phase 2/3 clinical trial for glioblastoma multiforme (GBM) has now been activated in 26 US sites as of August 16, 2021.
The GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment) trial is a patient-centered, adaptive platform trial for registration evaluating multiple therapies for patients with newly diagnosed and recurrent GBM.
Since January 2021, GCAR has accelerated the pace of clinical site activation with increased awareness in the medical community of Kintara's arm of the study. GCAR plans to enroll 150-200 patients in the Kintara arm of the study at over 40 sites in the US and Canada with the potential to increase that total to 65 clinical trial centers worldwide.
"The entire Kintara team remains enthused by the pace at which our treatment arm is being activated in the study," said Kintara CEO, Saiid Zarrabian in a statement. "With 26 sites already active, including the recent addition of prestigious centers such as the Dana Farber Cancer Institute and Massachusetts General Hospital, we are delighted to witness GCAR's exceptional clinical trial execution capabilities that drew us to participate in this exciting and highly efficient registrational study."
Kintara Therapeutics Inc (NASDAQ:KTRA) (FRA:3DM) (OTCMKTS:DMPWW) has announced topline data results from the recurrent arm of its open-label, Phase 2 clinical study of its lead compound VAL-083 being conducted at the MD Anderson Cancer Center in Houston.
The Phase 2 trial is a two-arm, biomarker-driven study testing VAL-083 in glioblastoma multiforme (GBM) patients, who have an unmethylated promoter of the methylguanine DNA-methyltransferase (MGMT) gene. The recurrent arm of the study addressed patients who have been pre-treated with temozolomide prior to disease recurrence.
Kintara Therapeutics Inc (NASDAQ:KTRA) (OTCMKTS:DMPWW) (FRA:3DM), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, has announced its addition to the Russell Microcap Index.
The company said its addition will take place at the conclusion of the 2021 Russell Indexes' annual reconstitution, effective after the US market opens on June 28, according to a preliminary list of additions posted on June 4.
What management says
Kintara Therapeutics (NASDAQ:KTRA) Inc (NASDAQ:KTRA) CEO Saiid Zarrabian tells Proactive its VAL-083 treatment arm in the Global Coalition for Adaptive Research (GCAR) registrational Phase 2/3 clinical trial for glioblastoma multiforme (GBM) has now been activated in 26 US sites.
Zarrabian explains why speed of site enrollment is so important, and how the group managed to establish enrollment at sites within a span of a seven months. He says typically, it will take around 2 years to enroll at these kind of sites.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...FOR OUR FULL DISCLAIMER CLICK HERE